Serum annexin A2 levels in patients with colon cancer in comparison to healthy controls and in relation to tumor pathology

Medical Science Monitor

Volumn 20, Issue , 2014, Pages 1801-1807

  Gurluler, Ercument ^a   Guner, Osman Serhat ^b   Tumay, Latif Volkan ^b   Kucukmetin, Nurten Turkel ^a   Hizli, Banu ^b   Zorluoglu, Abdullah ^b  

^a ACIBADEM UNIVERSITY   (Turkey)

^b Acibadem Bursa Hospital   (Turkey)

Author keywords

Annexin A2; Colonic neoplasms; Neoplastic processes

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LIPOCORTIN 2; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER STAGING; COLON CANCER; COLONOSCOPY; CONTINUOUS INFUSION; CONTROLLED STUDY; DEMOGRAPHY; DISTANT METASTASIS; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; LOADING DRUG DOSE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PROTEIN EXPRESSION; SPECTROPHOTOMETRY; TUMOR DIFFERENTIATION; TUMOR GROWTH; TUMOR INVASION; TUMOR VOLUME; BLOOD; CASE CONTROL STUDY; COLON TUMOR; COMPARATIVE STUDY; PATHOLOGY;

ADULT; AGED; ANNEXIN A2; CASE-CONTROL STUDIES; COLONIC NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 84908140645     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.892319     Document Type: Article

References (25)

1. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. Cancer J Clin, 2010; 60: 277–300
2. Ponz de Leon M, Percesepe A: Pathogenesis of colorectal cancer. Dig Liver Dis, 2000; 32: 807–21
3. Frucht H: Molecular genetics of colorectal cancer, 2014 http://www.uptodate. com/contents/molecular-genetics-of-colorectal-cancer
4. Halama N, Herrmann C, Jaeger D, Herrmann T: Treatment with cetuximab, bevacizumab and irinotecan in heavily pretreated patients with metas tasized colorectal cancer. Anticancer Res, 2008; 28(6B): 4111–15
5. Meropol NJ, Schulman KA: Cost of cancer care: issues and implications. J Clin Oncol, 2007; 25: 180–86
6. Weizmann AV, Nguyen GC: Colon cancer screening in 2010: an up-date. Minerva Gastroenterol Dietol, 2010; 56: 181–88
7. Hewitson P, Glasziou P, Watson E et al: Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol, 2008; 103: 1541–49
8. Walsh JM, Terdiman JP: Colorectal cancer screening: scientific review. JAMA, 2003; 289: 1288–96
9. Toiyama Y, Takahashi M, Hur K et al: Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J Natl Cancer Inst, 2013; 105: 849–59
10. Waisman DM: Annexin II tetramer; structure and function. Mol Cell Biochem, 1995; 149–50: 301–22
11. Lokman NA, Ween MP, Oehler MK, Ricciardelli C: The role of annexin A2 in tumorigenesis and cancer progression. Cancer Microenviron, 2011; 4: 199–208
12. Guo C, Liu S, Greenaway F, Sun MZ: Potential role of annexin A7 in cancers. Clin Chim Acta, 2013; 423: 83–89
13. Zhang X, Liu S, Guo C et al: The association of Annexin A2 and cancers. Clin Transl Oncol, 2012; 14: 634–40
14. Chiang Y, Rizzino A, Sibennaller ZA et al: Specific down-regulation of annexin A2 expression in human cells interferes with cell proliferation. Mol Cell Biochem, 1999; 199: 139–47
15. Moss SE, Morgan RO: The annexins. Genome Biol, 2004; 5: 219
16. Edge SB, Byrd DR, Compton CC et al: AJCC Cancer Staging Manual. 7th ed. New York Springer; 2010
17. Hayes MJ, Moss SE: Annexins and disease. Biochem Biophys Res Commun, 2004; 322: 1166–70
18. Xin W, Rhodes DR, Ingold C et al: Dysregulation of the annexin family protein family is associated with prostate cancer progression. Am J Pathol, 2003; 162: 255–61
19. Kang JS, Calvo BF, Maygarden SJ et al: Dysregulation of annexin I protein expression in high-grade prostatic intraepithelial neoplasia and prostate cancer. Clin Cancer Res, 2002; 8: 117–23
20. Pena-Alonso E, Rodrigo JP, Parra IC et al: Annexin A2 localizes to the basal epithelial layer and is down-regulated in dysplasia and head and neck squamous cell carcinoma. Cancer Lett, 2008; 263: 89–98
21. Emoto K, Yamata Y, Swada H et al: Annexin II overexpression correlates with stromal tenascin C overexpression: a prognostic marker in colorectal carcinoma. Cancer, 2001; 92: 1419–26
22. Katayama M, Nakano H, Ishiuchi A et al: Protein pattern difference in the colon cancer cell lines examined by two-dimensional differential in gelelectrophoresis and mass spectrometry. Surg Today, 2006; 36: 1085–93
23. Yang T, Peng H, Wang J et al: Prognostic and diagnostic significance of annexin A2 in colorectal cancer. Colorectal Dis, 2013; 15: e373–81
24. Singh P: Role of Annexin-II in GI cancers: interaction with gastrins/progastrins. Cancer Lett, 2007; 252: 19–35
25. Zhang HJ, Yao DF, Yao M et al: Expression characteristics and diagnostic value of annexin A2 in hepatocellular carcinoma. World J Gastroenterol, 2012; 18: 5897–904